SofosbuvirThird Party Manufacturing in India

Sofosbuvir is a direct-acting antiviral agent that targets the hepatitis C virus (HCV) at a fundamental level of its replication cycle. It is a nucleotide prodrug that requires intracellular activation to become pharmacologically active. After oral administration, sofosbuvir is efficiently taken up by hepatocytes, where cellular kinases sequentially phosphorylate it to its active triphosphate form, GS-461203. This active metabolite structurally mimics the natural nucleotide uridine triphosphate. The HCV NS5B RNA-dependent RNA polymerase, which is essential for viral RNA replication, incorporates GS-461203 into the growing viral RNA strand in place of uridine. Once incorporated, the unique 2-fluoro and 2-methyl modifications on the ribose ring of sofosbuvir create a steric clash that prevents the addition of the next nucleotide. This results in obligate chain termination, halting viral RNA synthesis and preventing the production of new viral genomes. Sofosbuvir has a high barrier to resistance because the active site of NS5B is highly conserved across all HCV genotypes. It exhibits selective toxicity by targeting a viral enzyme that has no close human counterpart, which contributes to its favourable safety profile. Sofosbuvir must always be used in combination with other antiviral agents to achieve sustained virologic response and prevent resistance.

Therapeutic Uses

Sofosbuvir is prescribed for the treatment of:

• Chronic Hepatitis C Genotype 1: Used in combination with ledipasvir (Harvoni) or daclatasvir for the treatment of genotype 1 infection in both treatment-naive and treatment-experienced patients.
• Chronic Hepatitis C Genotype 2 and 3: Used in combination with ribavirin with or without peginterferon alfa for genotypes 2 and 3, which are prevalent in the Indian subcontinent.
• Chronic Hepatitis C Genotype 4, 5, and 6: Effective across all major HCV genotypes, making it a pan-genotypic treatment option when combined with appropriate partners.
• HCV-HIV Co-Infection: Indicated for patients with HCV-HIV co-infection, with efficacy outcomes comparable to HCV mono-infected patients.
• Pre-Liver Transplant Patients: Used to prevent HCV reinfection in patients awaiting liver transplantation due to HCV-related hepatocellular carcinoma.

Why Manufacturers Choose Sofosbuvir

Sofosbuvir revolutionized hepatitis C treatment and remains one of the highest-demand antiviral molecules in the Indian pharmaceutical market. India is the world's largest manufacturer of generic sofosbuvir, supplying affordable treatment to millions of patients across Asia, Africa, and Latin America. The expiry of key patents has opened the market for Indian manufacturers to produce and export sofosbuvir to over 100 countries. The manufacturing process involves complex nucleotide chemistry and stereoselective synthesis, which creates a technical barrier to entry and allows established manufacturers to command premium pricing. The molecule is available as 400mg tablets and is often co-formulated with ledipasvir or velpatasvir as fixed-dose combinations. For PCD franchise operators, sofosbuvir products offer high per-unit margins and serve a patient population with strong treatment motivation. Indian manufacturers benefit from WHO prequalification and US FDA approvals for sofosbuvir, enabling access to institutional tenders and global health organization purchases.

This makes Sofosbuvir one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.